Seres Therapeutics (MCRB) Announces New Phase 2 SER-109 Study in Patients with Multiply Recurrent C. Difficile
Tweet Send to a Friend
Seres Therapeutics Inc., (NASDAQ: MCRB), a leading microbiome therapeutics platform company, today announced plans to initiate a new SER-109 Phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
